210 related articles for article (PubMed ID: 33628601)
21. The neutrophil-to-lymphocyte ratio (NLR) predicts short-term and long-term outcomes in gastric cancer patients.
Miyamoto R; Inagawa S; Sano N; Tadano S; Adachi S; Yamamoto M
Eur J Surg Oncol; 2018 May; 44(5):607-612. PubMed ID: 29478743
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the prognostic value of tumour- and patient-related factors in patients undergoing potentially curative resection of oesophageal cancer.
Dutta S; Crumley AB; Fullarton GM; Horgan PG; McMillan DC
World J Surg; 2011 Aug; 35(8):1861-6. PubMed ID: 21538187
[TBL] [Abstract][Full Text] [Related]
23. Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ?
Kneuertz PJ; Hofstetter WL; Chiang YJ; Das P; Blum M; Elimova E; Mansfield P; Ajani J; Badgwell B
Ann Surg Oncol; 2016 Feb; 23(2):626-32. PubMed ID: 26564243
[TBL] [Abstract][Full Text] [Related]
24. Pre-treatment Peripheral Neutrophil-Lymphocyte Ratio as a Prognostic Marker in Gastric Cancer.
Magdy M; Hussein T; Ezzat A; Gaballah A
J Gastrointest Cancer; 2019 Dec; 50(4):763-768. PubMed ID: 30058031
[TBL] [Abstract][Full Text] [Related]
25. Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer.
Sharaiha RZ; Halazun KJ; Mirza F; Port JL; Lee PC; Neugut AI; Altorki NK; Abrams JA
Ann Surg Oncol; 2011 Nov; 18(12):3362-9. PubMed ID: 21547702
[TBL] [Abstract][Full Text] [Related]
26. Challenges in the treatment of gastroesophageal junction cancer.
Liakakos T
World J Surg; 2011 Jun; 35(6):1409-10; author reply 1411. PubMed ID: 21301836
[No Abstract] [Full Text] [Related]
27. Perioperative Treatment, Not Surgical Approach, Influences Overall Survival in Patients with Gastroesophageal Junction Tumors: A Nationwide, Population-Based Study in The Netherlands.
Koëter M; Parry K; Verhoeven RH; Luyer MD; Ruurda JP; van Hillegersberg R; Lemmens VE; Nieuwenhuijzen GA
Ann Surg Oncol; 2016 May; 23(5):1632-8. PubMed ID: 26727917
[TBL] [Abstract][Full Text] [Related]
28. Predictive Value of the Neutrophil/Lymphocyte Ratio in Peritoneal and/or Metastatic Disease at Staging Laparoscopy for Gastric and Esophageal Adenocarcinoma.
Grenader T; Plotkin Y; Mohammadi B; Dawas K; Hashemi M; Mughal M; Bridgewater JA
J Gastrointest Cancer; 2015 Sep; 46(3):267-71. PubMed ID: 25952408
[TBL] [Abstract][Full Text] [Related]
29. Impact of Body Mass Index on Complications and Survival after Surgery for Esophageal and Gastro-Esophageal-Junction Cancer.
Kruhlikava I; Kirkegård J; Mortensen FV; Kjær DW
Scand J Surg; 2017 Dec; 106(4):305-310. PubMed ID: 28737095
[TBL] [Abstract][Full Text] [Related]
30. [Survival comparison of Siewert II adenocarcinoma of esophagogastric junction between transthoracic and transabdominal approaches:a joint data analysis of thoracic and gastrointestinal surgery].
Yang S; Yuan Y; Hu H; Li R; Liu K; Zhang W; Yang K; Yang Y; Bai D; Chen X; Zhou Z; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):132-142. PubMed ID: 30799535
[TBL] [Abstract][Full Text] [Related]
31. Association of the age-adjusted Charlson Comorbidity Index and systemic inflammation with survival in gastric cancer patients after radical gastrectomy.
Lin JX; Huang YQ; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu R; Huang ZN; Lin JL; Zheng CH; Huang CM; Li P
Eur J Surg Oncol; 2019 Dec; 45(12):2465-2472. PubMed ID: 31350072
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers.
Park DJ; Yoon C; Thomas N; Ku GY; Janjigian YY; Kelsen DP; Ilson DH; Goodman KA; Tang LH; Strong VE; Coit DG; Yoon SS
Ann Surg Oncol; 2014 Apr; 21(4):1130-7. PubMed ID: 24370903
[TBL] [Abstract][Full Text] [Related]
33. Neutrophil-lymphocyte ratio is associated with prognosis in patients who underwent potentially curative resection for gastric cancer.
Szor DJ; Roncon Dias A; Pereira MA; Ramos MFKP; Zilberstein B; Cecconello I; Ribeiro U
J Surg Oncol; 2018 Apr; 117(5):851-857. PubMed ID: 29509963
[TBL] [Abstract][Full Text] [Related]
34. Application of platelet/lymphocyte and neutrophil/lymphocyte ratios in early diagnosis and prognostic prediction in patients with resectable gastric cancer.
Lian L; Xia YY; Zhou C; Shen XM; Li XL; Han SG; Zheng Y; Mao ZQ; Gong FR; Wu MY; Chen K; Tao M; Li W
Cancer Biomark; 2015; 15(6):899-907. PubMed ID: 26444485
[TBL] [Abstract][Full Text] [Related]
35. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
Molina R; Lamarca A; Martínez-Amores B; Gutiérrez A; Blázquez A; López A; Granell J; Álvarez-Mon M
Eur J Surg Oncol; 2013 Aug; 39(8):814-22. PubMed ID: 23755989
[TBL] [Abstract][Full Text] [Related]
36. Factors predicting survival in patients with proximal gastric carcinoma involving the esophagus.
Zhang YF; Shi J; Yu HP; Feng AN; Fan XS; Lauwers GY; Mashimo H; Gold JS; Chen G; Huang Q
World J Gastroenterol; 2012 Jul; 18(27):3602-9. PubMed ID: 22826627
[TBL] [Abstract][Full Text] [Related]
37. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer.
Reim D; Gertler R; Novotny A; Becker K; zum Büschenfelde CM; Ebert M; Dobritz M; Langer R; Hoefler H; Friess H; Schumacher C
Ann Surg Oncol; 2012 Jul; 19(7):2108-18. PubMed ID: 22130620
[TBL] [Abstract][Full Text] [Related]
38. Neutrophil to lymphocyte ratio as a predictor of response to neoadjuvant chemotherapy and survival in oesophageal adenocarcinoma.
Powell AGMT; Chin C; Coxon AH; Chalishazar A; Christian A; Roberts SA; Lewis WG
BJS Open; 2020 Jun; 4(3):416-423. PubMed ID: 32232963
[TBL] [Abstract][Full Text] [Related]
39. A nationwide retrospective study of perioperative chemotherapy for gastroesophageal adenocarcinoma: tolerability, outcome, and prognostic factors.
Larsen AC; Holländer C; Duval L; Schønnemann K; Achiam M; Pfeiffer P; Yilmaz MK; Thorlacius-Ussing O; Bæksgaard L; Ladekarl M
Ann Surg Oncol; 2015 May; 22(5):1540-7. PubMed ID: 25348777
[TBL] [Abstract][Full Text] [Related]
40. Improved survival in resected oesophageal and gastric adenocarcinomas over a decade: the Royal Marsden experience 2001-2010.
Fontana E; Smyth EC; Cunningham D; Rao S; Watkins D; Allum WH; Thompson J; Waddell T; Peckitt C; Chau I; Starling N
Gastric Cancer; 2016 Oct; 19(4):1114-1124. PubMed ID: 26541768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
